Drug intelligence / Profile preview

edatrexate

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

Edatrexate is a synthetic antifolate and structural analog of methotrexate. It was developed as an antineoplastic agent for the treatment of various cancers. Edatrexate acts by inhibiting dihydrofolate reductase (DHFR), thereby blocking DNA synthesis and cell division in rapidly proliferating cells. It was investigated primarily for use in non-small cell lung cancer and other solid tumors but did not achieve widespread clinical adoption due to limited efficacy compared to existing therapies and notable toxicity.

Other names: edatrexate10-ethyl-deazaaminopterinEDAMBMS-180680BMS180680BMS 180680

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on edatrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on edatrexate.

Explore the full profile